Loading...
Market
How many new prescriptions for Wegovy will be issued in Europe by March 31, 2025?
2
Resolution / Starting Odds
Below 50,000 • 25%
50,000 to 100,000 • 25%
100,000 to 150,000 • 25%
Above 150,000 • 25%
Data from European health agencies and Novo Nordisk's reports
Story
Novo Nordisk's GLP-1 Wegovy Receives EMA Approval for Heart Failure Label Update on Thursday
Sep 19, 2024, 08:00 PM
Novo Nordisk, the Danish drugmaker, announced that its drug Wegovy has received a positive opinion from the European Medicines Agency for a label update. The update will reflect reduced heart failure symptoms and improved physical function in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). The recommendation, announced on Thursday, is based on results from the STEP HFpEF trials. Wegovy is the first GLP-1 medication to receive such an endorsement for obesity-related heart failure.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by 0-10% • 25%
Decrease by 0-10% • 25%
Decrease by more than 10% • 25%
< 1 million • 33%
1 - 2 million • 33%
> 2 million • 34%
0 • 25%
1-3 • 25%
4-6 • 25%
More than 6 • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
0-5 countries • 25%
6-10 countries • 25%
11-15 countries • 25%
More than 15 countries • 25%
Under 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Over 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%